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microRnAs (miRnAs) interact with 3′-untranslated regions of messenger RnAs to restrict 
expression  of  most  protein-coding  genes  during  normal  development  and  cancer.  RnA-
binding proteins (RBPs) can control the biogenesis, stability and activity of miRnAs. Here we   
identify RBm38 in a genetic screen for RBPs whose expression controls miRnA access to target 
mRnAs. RBm38 is induced by p53 and its ability to modulate miRnA-mediated repression   
is required for proper p53 function. In contrast, RBm38 shows lower propensity to block the 
action of the p53-controlled miR-34a on sIRT1. Target selectivity is determined by the interaction 
of RBm38 with uridine-rich regions near miRnA target sequences. Furthermore, in large cohorts 
of human breast cancer, reduced RBm38 expression by promoter hypermethylation correlates 
with wild-type p53 status. Thus, our results indicate a novel layer of p53 gene regulation, which 
is required for its tumour suppressive function. 
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R
egulation  of  gene  expression  is  a  fundamental  and  multi-
layered process used by the cell to orchestrate or modulate 
organism  development,  homeostasis  and  environmental 
adaptation, among others. Each step involved in the pathway of 
gene expression, from RNA transcription to protein production, 
including  pre-messenger  RNA  splicing  and  polyadenylation,  as 
well as mRNA stability, transport and translation, is tightly con-
trolled by a variety of protein and RNA effectors. MicroRNAs have 
recently gained attention owing to the magnitude of their influence 
on mRNA stability and protein translation. MicroRNAs are small 
non-coding  RNAs  able  to  direct  translation  repression,  mRNA   
degradation, or a combination of the two1,2. Interestingly, bioinfor-
matic predictions suggest that mammalian miRNAs could influence 
up to 60% of all protein-coding genes, supporting the importance of 
these non-coding RNA regulators3.
Reflecting the broad impact of miRNAs on gene regulation, it 
is not surprising to find deregulation of miRNA expression in a 
variety of cancers as well as in some inflammatory, neurodegenera-
tive and cardiovascular diseases4–11. Deregulation of miRNAs can   
occur through genetic alterations that can affect the production 
of the primary miRNA transcript, processing to mature miRNA,   
and  influence  miRNA–mRNA  interaction12–16.  Interestingly,  an   
association  has  been  established  between  colon  cancer  and  two 
frameshift  mutations  in  the  TARBP2  gene,  an  RNA-binding   
protein  regulating  DICER  stability  and  miRNA  processing17.   
Both frameshifts introduce premature stop codons that produce a 
truncated dysfunctional TARBP2 that is unable to stabilize DICER, 
causing  a  lower  miRNA  production,  and  favouring  tumorigenic 
growth.
RNA-binding  proteins  (RBPs)  have  a  fundamental  role  in 
posttranscriptional control of gene expression by regulating and   
coordinating  the  different  processes  of  mRNA  metabolism  and 
translation18. One of the mechanisms used in this regulation is the 
modulation of miRNA production and activity. An example is the 
mechanism involving the RBP lin-28 and the miRNA let-7. By bind-
ing to the terminal loop of let-7 precursors, lin-28 interferes with 
the processing mediated by DGCR8 or DICER, contributing to the 
maintenance of an undifferentiated state19–22. Additionally, miRNA 
activity  can  be  enhanced  or  hindered  by  RBPs  bound  to  target 
mRNA. For example, the RBP HuR binds to the 3′UTR of CAT-1 
mRNA and relieves the miR-122 repression during different stress 
conditions23. Alternatively, the RBP pumilio binds to p27-3′UTR 
and induces a local change in RNA structure to favour the binding 
of miR-221 and miR-222 (ref. 24).
Many stress conditions activate the tumour suppressor p53 to 
coordinate an adequate gene expression response. Interestingly, p53 
function is partly mediated through the regulation of miRNAs and 
RBPs. During DNA damage, p53 interacts with both DGCR8 and 
DDX5 to enhance the processing of several miRNAs25. In addition, 
p53 directly activates the miR-34 family, which in turn interferes 
with the expression of several cell cycle and survival promoting 
genes26,27. The stress-activated p53 can also promote the induction 
of RBPs. For example, the double-stranded-RNA-binding zinc fin-
ger ZMAT3 is a direct target of p53 and is capable of binding p53-
3′UTR, to increase its stability28. The RNA-binding protein RBM38 
is also targeted by p53 and is required, by unknown mechanism, to 
efficiently induce p21 protein levels during stress conditions29.
Here  we  report  that  RBM38  is  required  to  decrease  miRNA 
accessibility on a number of p53-induced transcripts, allowing an 
optimal target gene induction and cell cycle control. In contrast, 
RBM38 does not significantly affect the activity of miR-34a, a p53 
target miRNA that is required for p53 function, on its target SIRT1. 
A combination of in vivo and in vitro binding assays, and mutational 
analysis, shows that binding of RBM38 to target 3′UTRs is essential 
to control the activity of specific miRNAs. Altogether, we propose 
that RBM38 supports p53 in initiating an efficient cellular stress 
response by selective blocking of miRNA action on different p53-
induced mRNAs.
Results
A functional genetic screen to identify regulators of miRNAs.   
To identify regulators of miRNA activity, we performed an RBP 
screen.  We  constructed  an  expression  library  of  ~100  RBPs 
(Supplementary Table S1) and used as bait miR-150 and its target 
c-Myb-3′UTR  cloned  in  the  psiCHECK2  dual  luciferase  vector   
(Fig. 1a)30. We co-transfected c-Myb-3′UTR, the miR-150 or the 
control miR-206 with the RBP library into U2OS cells and calculated 
the impact of miR-150 on Renilla/Firefly luciferase ratios (Fig. 1b).   
Control  transfections  (red)  showed  the  expected  2–2.5-fold 
reduction in gene expression by miR-150, and ectopic expression of 
Dnd1 (green) blocked miRNA effect, as reported previously31. For 
validation, we selected 8 RBPs that presented the most significant 
inhibitory  effect  on  miR-150  function,  but  could  confirm  only 
RBM38 (Fig. 1c).
Interplay  between  RBM38  and  miRNAs.  RBM38  contains  one 
RNA recognition motif (RRM) domain. We, therefore, examined 
whether the miRNA-related function of RBM38 is dependent on the 
RNA-binding activity of its RRM domain by mutating two evolu-
tionary conserved residues, Y77 and K103 (Fig. 1d) that are involved   
in  canonical  RRM–RNA  binding32.  In  vitro  NMR  assays  show   
that the Y77A/K103E mutant is folded and non-aggregated and 
that, in contrast to RBM38wt, does not bind to RNA (Fig. 1e; Supple-
mentary Fig. S1). Overexpression of RBM38mut in both U2OS and 
MCF-7  cells  did  not  affect  miR-150  activity,  whereas  RBM38wt 
diminished miR-150 function (Fig. 1f). Thus, binding to RNA is 
required by RBM38 to inhibit miR-150 activity.
Interestingly, like Dnd1 (ref. 31), RBM38 function was connected 
to miRNAs. When we mutated c-Myb-3′UTR in the miR-150 tar-
get  sequences  (c-Myb-short-mut-3′UTR  or  c-Mybs-mut-3′UTR), 
no  regulation  by  RBM38  was  observed  (Fig.  1g;  Supplementary   
Fig. S2). Moreover, transfection of an efficient short hairpin RNA 
(shRNA) against RBM38 (Fig. 1h; Supplementary Fig. S3) enhanced 
the inhibition mediated by miR-150 on c-Mybs-wt-3′UTR. This effect 
was specific and miRNA-related, as no significant effect was seen 
on c-Mybs-mut reporter (Fig. 1h). Of note, both the overexpression   
and knockdown of endogenous RBM38 were not associated with 
significant  changes  in  mature  miRNA  expression  and  localiza-
tion (Fig. 1i; Supplementary Figs S4 and S5). However, the effect 
of  RBM38  was  not  restricted  to  miR-150/c-Myb-3′UTR,  as  the   
miR-206-mediated repression of Cx43-3′UTR was equally respon-
sive  to  RBM38  (Supplementary  Fig.  S6).  Altogether,  our  results 
are consistent with a model whereby binding of RBM38 to target 
mRNAs restricts miRNA accessibility.
RBM38, cellular stress and cell cycle. RBM38 levels were shown 
to increase following DNA damage through p53, an effect that is 
required for p21 stimulation and cell cycle arrest29. Indeed, in MCF-7,   
U2OS and ZR-75.1 cells, RBM38 mRNA levels increased 2–3-fold 
in 24 h following doxorubicin treatment (Fig. 2a). This effect was 
diminished in cells transfected with a p53kd vector (Fig. 2b). More-
over, the expression of endogenous RBM38 was required to main-
tain normal levels of p21 in cycling cells, and induced high levels 
of p21 in DNA-damaged cells. First, Figure 2c shows that inhibi-
tion of RBM38 expression by two effective small interfering RNAs   
(siRNAs) reduced p21 protein levels. Second, loss-of RBM38 expres-
sion hampered the accumulation of p21 following DNA damage 
inflicted by doxorubicin in MCF-7 and U2OS cells (Fig. 2d). This, 
importantly, was despite normal induction of p53.
Next,  we  examined  the  role  of  RBM38  in  enforcing  proper   
cell cycle checkpoints in response to DNA damage. We analysed 
expression profiles in control and RBM38kd MCF-7 cells that were ARTICLE     
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incubated with and without doxorubicin for 24 h. Although a large 
portion  of  the  transcriptional  response  to  doxorubicin  was  not 
affected by knocking down RBM38, a major cluster of more than 
100 genes was downregulated in response to doxorubicin in control, 
but not in RBM38kd cells (Supplementary Fig. S7). Importantly,   
this cluster was significantly enriched for cell-cycle-related genes 
(Supplementary  Table  S2).  The  downregulation  of  these  genes 
reflects the strong activation of cell cycle arrest in response to the 
DNA damage-associated stress in the control cells, as well as the 
defect in this response when RBM38 expression is suppressed.
We also observed that knocking down RBM38 undermines the 
activation of cell cycle arrest in response to genotoxic stresses. As 
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Figure 1 | RBM38 counteracts miR-150-mediated repression of c-Myb-3′UTR. (a) screen illustration. u2os cells were transfected with psiCHECK2-c-
myb-3′uTR, the control miR-206 or miR-150 construct. The RBP library was then transfected and relative renilla/firefly levels were assessed 48 h later. (b) 
RBPs were plotted according to their miR-150/miR-206 ratios. Positive (green) and negative (red) controls as well as the mean (black line)  ±  
s.d. (shaded area) are displayed. (c) screen validation using same settings as in (a). The relative luciferase signals derived from the miR-150/miR-206 
ratios were normalized to the control reaction and the latter was arbitrarily set to 1. RBm38 is shown in blue. Error bars represent standard deviation of 
technical replicates, n = 3. (d) secondary structure of the human RBm38 RRm domain. The residues Y77 and K103, which are mutated in RBm38mut, are 
displayed in red. (e) overlay of 15n 1H correlation spectra recorded during the titration of wild-type (left panel) and mutant (right panel) RBm38 with an 
5′-uuuuuu-3′ (u6) RnA oligo at 27 °C. spectra are recorded at protein:RnA ratio of 1:0 (red), 1:1 (purple) and 1:3 (blue). (f) u2os and mCF-7 cells were 
co-transfected with the indicated plasmids as in (a) and the luciferase signals were processed as in (c). Protein levels of RBm38 wild type and mutant are 
also shown. (g) u2os cells were transfected with either the wild-type or the mutant c-myb-short-3′uTR (c-mybs-wt or c-mybs-mut) and the indicated 
plasmids. The luciferase signals were processed as in (c). (h) u2os cells were transfected with the reporters mentioned in (g) together with a control 
or a knockdown against RBm38. The luciferase signals were processed as in (c). (i) The level of various mature miRnAs was measured in u2os cells 
transfected with scrambled siRnA (Ctrl) or siRnA against RBm38 (upper panel) and with an empty vector (Ctrl) or RBm38 expression vector (lower 
panel). GAPDH levels were used as an internal control for normalization. Error bars represent standard deviation of technical replicates, n = 3. Data in  
(f,g,h) are representative of three independent experiments (mean ± s.d., *P < 0.05; **P < 0.005, two-tailed student’s t-test).ARTICLE
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shown  in  Figure  2e  and  Supplementary  Figure  S8a,  inhibition  of 
RBM38 expression in U2OS and HCT116 cells treated with ion-
izing radiation or Nutlin-3, resulted in a reduction of ~10–15% of 
the G1-arrested cells. Similar results were also achieved with 3 dif-
ferent siRNAs against RBM38 (Supplementary Fig. S8b,c). Last, to 
examine whether the effect of RBM38 on p21 expression was medi-
ated through p21-3′UTR, we cloned the p21-3′UTR downstream of 
Renilla luciferase in the psiCHECK2 vector. Co-transfection experi-
ments with two effective RBM38 siRNAs showed that most, if not 
all, of RBM38 effect on p21 was mediated through the p21-3′UTR   
(Fig. 2f). Thus, our results confirm that RBM38 is a downstream tar-
get of p53 required for maintaining p21 protein levels during normal 
proliferation and following genotoxic stress through the p21-3′UTR.
RBM38 blocks miRNA-mediated repression of p53 target genes. 
Our  results,  thus  far,  suggest  that  RBM38  induces  gene  expres-
sion by inhibiting miRNA activity on target 3′UTRs. Particularly,   
p53-dependent  maintenance  of  high-p21-protein  level  follow-
ing DNA damage requires RBM38. These observations raised two 
issues: does RBM38 counteract the miRNA-mediated repression of 
diverse p53 target genes?; how specific is the function of RBM38? 
To address the first question, we examined the effect of RBM38 
overexpression and knockdown on the 3′UTR of several known 
direct transcriptional targets of p53 (Fig. 3a). Similar to the p21-
3′UTR,  RBM38wt  induced  the  expression  of  Renilla  luciferase 
when conjugated with the 3′UTRs of RBM38 itself, PCNA, DDIT4, 
TNFRSF10B,  LATS2  and  IER5  (Fig.  3b).  Similarly,  knocking 
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Figure 2 | RBM38 is induced by p53 and is required to sustain p21 levels. (a) Three different p53wt cell lines (u2os, mCF-7 and ZR-75.1) were treated 
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down RBM38 affected the vast majority of these 3′UTRs (Fig. 3c).   
This  indicates  that  RBM38  broadly  functions  to  assist  p53  in   
inducing its target genes. However, we also noticed that RBM38 
function  is  not  limited  to  p53-target  genes  (Supplementary   
Fig. S9). To examine if this function is miRNA-dependent (Fig. 
3d), we identified a few miRNAs that are able to repress RBM38, 
p21,  DDIT4  and  LATS2  (Supplementary  Fig.  S10).  In  all  cases, 
miRNA-mediated repression was largely counteracted by RBM38 
overexpression (Fig. 3e). These results suggest that RBM38 helps 
to maintain the expression of p53 target genes, at least in part, by 
inhibiting targeting miRNAs.
Specificity of RBM38 function. Beyond activating protein-cod-
ing genes, p53 also enhances miRNA processing in general25 and 
activates miR-34a in particular26. This raises the question of specifi-
city, as the induction of RBM38 may block p53-mediated miR-34a 
function. To address this issue, we examined SIRT1, a prominent 
and biologically relevant miR-34a target (Fig. 3f). Indeed, trans-
fection  of  miR-34a  inhibited  SIRT1-3′UTR  expression,  but  not   
c-Myb-3′UTR (Supplementary Fig. S11). However, in contrast to 
the direct p53-target genes examined above, RBM38 overexpres-
sion had no significant effect on the repression of SIRT1-3′UTR 
by  miR-34a  (Fig.  3g).  Moreover,  RBM38  did  not  influence  the   
levels of miR-34a (Supplementary Fig. S12). Similar results were 
also obtained with FOXP1-3′UTR, another target of the miR-34a 
(Supplementary  Fig.  S13).  Conversely,  loss-of  RBM38  induces 
miR-150-mediated  inhibition  of  c-Myb-3′UTR,  while  no  effects 
were observed on miR-34a-mediated inhibition of SIRT1-3′UTR 
(Fig. 3h). These experiments show that RBM38 exhibits, to some 
extent, target specificity.
To  uncover  the  molecular  mechanism  underlying  RBM38-
selective inhibition of miRNA activity, we mapped RBM38-bind-
ing sites in HeLa cells by iCLIP33. Statistical analysis revealed that 
RBM38 binds preferentially to 3′UTRs (Supplementary Fig. S14a). 
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The distribution of target sites along the 3′UTR was not even, as 
a greater occupancy was observed at the beginning and at the   
end  of  the  3′UTRs  (Supplementary  Fig.  S14b).  This  pattern  is   
similar to the miRNA binding profile and therefore suggested a 
relation  between  miRNA  and  RBM38  binding  to  the  mRNA34. 
Intersection  with  the  expression  dataset  detected  a  mild  but   
statistically significant repression of the targets bound by RBM38 
in the knocked-down samples (Supplementary Fig. S14c). De-novo 
motif discovery analysis revealed that, RBM38 is most often found 
bound  to  uridine-rich  RNA  regions  (URRs)  (Supplementary   
Fig. S14d). Supporting this observation, in vitro binding assays 
also  demonstrated  that  RBM38  RRM  binds  with  high  affinity   
to  polyU  RNA  oligos  (Fig.  1e).  Interestingly,  although  the  two 
miR-150-binding sites in the c-Myb-3′UTR contained URRs, the 
equivalent region on SIRT1-3′UTR (miR-34a-binding sites), did 
not. This suggests that the presence of URRs in the vicinity of 
miRNA target sites determines target selectivity of RBM38 in our 
functional assays.
To study in more detail the RBM38 interaction region on the 
3′UTRs, we replaced the two miR-150-binding sites in c-Myb-3′UTR 
with the miR-34a sites of SIRT1-3′UTR (Fig. 4a; Supplementary   
Fig. S2). As expected, overexpression of miR-34a repressed c-Mybs- 
34a-3′UTR  reporter,  while  overexpression  of  miR-150  inhibited 
c-Mybs-wt-3′UTR.  Consistently,  ectopic  expression  of  RBM38wt 
completely diminished miR-150 function on the c-Mybswt-3′UTR, 
but had only a slight effect on the miR-34a-mediated repression of 
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the c-Mybs34a-3′UTR (Fig. 4b). Inversely, replacing the two miR-
34a-binding  sites  in  the  SIRT1s-3′UTR  (Fig.  4a;  Supplementary   
Fig. S2) with the miR-150 sites of the c-Myb-3′UTR, increased the 
SIRT1s-3′UTR sensitivity to RBM38 function (Fig. 4c). To directly 
link functional specificity to RRM–RNA binding, we measured the 
affinity of the RBM38 RRM domain for the miR-150 and miR-34a   
sites on the c-Myb-3′UTR and SIRT1-3′UTR, respectively. In vitro 
NMR assays showed that the in vivo target RNAs bind with sub-
stantially higher affinity than the non-target ones (Supplementary   
Fig. S15 and Supplementary Table S3). One important question is, if 
recognition of p21, which is targeted by RBM38, but only has a short 
U stretch sequence compared with c-Myb (albeit it does contain 
U/G-rich stretches, like c-Myb), is mediated by the RRM domain. 
To answer this, we tested RBM38 RRM affinity for the miRNA seed 
site  on  the  p21-3′UTR  and  compared  this  affinity  with  the  one 
obtained for the SIRT1 and c-Myb RNAs. RBM38 binds to p21 with 
an affinity similar to the binding to c-Myb, which is substantially 
stronger than SIRT1, confirming a direct link between RRM–RNA 
binding and target specificity (Fig. 4d and Supplementary Fig. S15) 
and  showing  that  the  iCLIP  data,  although  consistent  with  our   
affinity measurements and, in general, with the observed in vivo  
targeting, are not strictly predictive.
RBM38 restricts Ago2 accessibility to p21 mRNA. Mechanisti-
cally, we hypothesized that RBM38 could interfere with miRNA 
function  by  binding  to  target  mRNAs  and  preventing  miRNA 
accessibility.  To  test  this,  we  generated  a  Tet-On  inducible  sys-
tem for RBM38-HA in U2OS cells. Figure 4e shows the induction   
of GFP and RBM38-HA in this system. We subsequently treated   
both  induced  cell  lines  with  Nutlin-3,  IPed  Ago2  (Fig.  4f)  and 
RBM38-HA,  and  examined  their  interaction  with  p21  mRNA.   
As expected, we found p21 mRNA bound to RBM38-HA (Supple-
mentary Fig. S16). In contrast, lower p21 mRNA levels were detected 
in  Ago2  IPs  from  RBM38-induced  cells  (Fig.  4g).  Moreover,  as 
shown in Figure 4h, Ago2-bound miRNA-17 levels remain stable 
with RBM38 induction. Altogether, these results strongly support 
RBM38’s function in binding to mRNAs and restricting miRNA 
accessibility.
RBM38 function is linked to miRNA. To further assess the con-
nection between RBM38 and miRNAs, we overexpressed RBM38 
in HCT116 wild type and in HCT116 DICER exon 5 knockout 
(ex5 − / − ) cells. As shown in Figure 5a, the levels of mature miR-
NAs are substantially lower in the HCT116ex5 − / −  cells compared 
with HCT116wt. We then postulated that knocking down RBM38 
should preferentially reduce p21 protein levels in HCT116wt, where 
the ratio miRNAs/RBM38 is high. Indeed, knocking down RBM38 
in HCT116wt cells resulted in a marked reduction in p21 activation 
following DNA damage treatment, while p21 was still accumulat-
ing in HCT116ex5 − / −  (Fig. 5b). Remarkably, the induction of p21 in 
RBM38-knocked down HCT116ex5 − / −  cells was prevented by the 
addition of the miR-17 duplex (Supplementary Fig. S17). This sug-
gests that a substantial part of the regulation of p21 by RBM38 is 
carried out through derepression of targeting miRNA activity.
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Next, we examined the effect of RBM38 on the p53 response by 
treating cells with Nutlin-3, a specific inhibitor of the p53–mdm2 
interaction. Cell cycle analyses revealed that whereas the response 
of  HCT116wt  to  Nutlin-3  was  effectively  reduced  when  RBM38 
was suppressed ( − 17% G1), HCT116ex5 − / −  cells showed a reduced 
response ( − 7% G1) (Fig. 5c). As RBM38 counteracts the repres-
sion of the miR-17 family on the p21-3′UTR (Fig. 3e; Supplemen-
tary Fig. S10c)35, we tested whether anti-miR-17 could rescue the 
loss of p21 induction by DNA damage in RBM38 knockdown U2OS 
cells. Figure 5d shows that the addition of anti-miR-17/106b pool 
to cells with RBM38kd largely rescued p21 levels following doxo-
rubicin treatment. Additionally, flow cytometry analysis revealed 
that whereas loss of RBM38 expression resulted in 12% loss of G1 
arrest, inhibition of miR-17/106b activity reduced this effect to 5% 
(Fig. 5e). Thus, our results indicate that RBM38 is required for opti-
mal induction of G1 arrest following DNA damage by shielding   
the 3′UTRs of prominent p53-target genes from targeting miRNAs.
Hypermethylation of RBM38 promoter in p53wt breast tumours. 
Next, we examined RBM38 expression levels in tumours charac-
terized with wt or mutant p53, as RBM38 expression is required 
for  p53  function.  In  two  independent  breast  cancer  cohorts36,37, 
we identified a significant reduction in RBM38 mRNA levels in 
the p53 wild-type subset, when compared with mutant p53 (Fig. 
6a; P = 3.55×10 − 9; Wilcoxon test). We therefore examined whether   
CpG methylation could underlie the reduced level of RBM38 in 
wt p53 breast cancer. Methylation status of CpG islands covering 
RBM38 promoter region was measured in a cohort of 102 breast 
cancer tumours, of which 44 harboured mutated p53. Importantly, 
while  RBM38  promoter  was  methylated  in  26%  of  the  p53-wt   
samples, only 7% of the p53-mutant tumours showed presence of 
methylation (Supplementary Table S4). Moreover, RBM38 expres-
sion was significantly reduced in the subset of samples in which 
its  promoter  was  found  methylated  (Fig.  6b;  P = 4.7×10 − 3;  Wil-
coxon test), pinpointing the inhibitory influence of methylation on   
RBM38 expression. To experimentally test the effect of DNA methyl-
ation on RBM38 expression, we examined the methylation status of 
RBM38 CpG islands in several breast cancer cell lines and identi-
fied two cell lines (MDA-MB-231 and MDA-MB-436) to be positive   
(Fig. 6c,d). Treatment of these two cell lines with 5-aza-2′-deoxy-
cytidine,  a  DNA  demethylating  agent,  induced  RBM38  expres-
sion by at least threefold (Fig. 6e). This supports an active silencing 
mechanism of RBM38 expression by DNA methylation at nearby 
CpG islands and proposes that this event participates in the tumori-
genesis process of wt p53 breast tumours by numbing p53 ability to 
activate its target genes.
Discussion
Our results portray a model whereby RBM38 potentially inhib-
its miRNA function on many mRNAs, whereas some mRNAs are   
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selectively  spared.  This  discrimination  operates  when  RBM38  is 
induced  in  a  p53-dependent  manner  following  DNA  damage. 
Although RBM38 supports the induction of several p53 mRNA 
targets by relieving miRNA repression, SIRT1, a target of miR-34a, 
which is a downstream target of p53, is spared (Fig. 7a). This allows 
for differential regulation of gene expression and optimal cell cycle 
response to DNA damage. Moreover, tumour data analysis revealed 
a correlation between DNA methylation of the RBM38 promoter 
region, low RBM38 expression levels, and wt p53 status, suggesting 
a tumour suppressive role of RBM38 in breast cancer (Fig. 7b).
p53  modulates  miRNA  production  and  biogenesis  at  several   
levels. It activates global miRNA production by associating with 
essential components of the miRNA biogenesis machinery. In addi-
tion, p53 activates miR-34a to induce growth arrest. Our results 
unravel an extra layer of miRNA regulation by p53 that relies on 
the modulation of the activity of specific miRNAs on p53 targets. 
We show that p53 induces the RNA-binding protein RBM38, which, 
in turn, limits the accessibility of miRNA sites on the 3′UTRs of 
its target gene transcripts. In contrast, the SIRT1-3′UTR, a down-
stream target of miR-34a, is not significantly affected by RBM38. 
This indicates that selective miRNA-mediated mechanisms act to 
enhance p53 function.
Here  we  constructed  an  expression  library  of  RNA-binding   
proteins,  which  was  subsequently  used  to  identify  new  RBPs 
involved in the regulation of miRNA activity. We identified RBM38 
as a specific inhibitor of miR-150 function on the c-Myb-3′UTR. 
Interestingly, the spectrum of action of RBM38 was not limited to   
miR-150 blocking but included many others (Fig. 3e; Supplementary   
Fig. S6). Analogously, our lab previously reported that the RNA-
binding  protein  Dnd1  was  able  to  block  the  access  of  miR-206   
to  Cx43-3′UTR  as  well  as  miR-372/373  to  LATS2-3′UTR31. 
Despite having a similar function and overlapping targets, Dnd1 
and RBM38 seem to have distinct ‘raison d’être’. Whereas Dnd1 is   
specifically expressed in germ cells, RBM38 expression is observed 
in many human cells and tissues. Furthermore, the RBMS1, 2 and 3 
homologues of Dnd1 have similar activity but an entirely different 
pattern of expression, indicating different roles in cell regulation. 
A context-dependent change in proteins regulating miRNAs is also 
observed in miRNA biogenesis, where the processing of let-7 pri-
miRNA is tuned by either lin-28 or KSRP protein, two proteins that 
are expressed in stem and somatic cells, respectively16,18,21,22. Alto-
gether, this argues that the specificity of action of miRNA-regulating 
RBPs is dictated by their expression pattern.
Our results indicate that p53 induces the RNA-binding protein 
RBM38 to influence the expression of several p53-target genes by 
blocking miRNA accessibility. Shu et al. recently identified RBM38 
as a direct target of p53 and linked it to the stability of basal and 
stress-induced  p21  transcripts29.  Here  we  confirm  this  observa-
tion and further extend it to other p53-target genes. Some of these 
genes are targets of miRNAs, and we show that RBM38 effectively 
counteracted the function of miR-17/106b on the p21-3′UTR, miR-
125b on the RBM38-3′UTR, miR-153 on the DDIT4-3′UTR, and 
miR-372/373 on the LATS2-3′UTR, providing a direct link between 
RBM38 and activity of specific miRNAs. Interestingly, it has recently 
been shown that RBM38 and the AU-rich-element-binding protein 
HuR can physically interact and collaborate to regulate p21 mRNA 
stability38. Bhattacharyya et al. previously demonstrated that dur-
ing  stress  HuR  translocates  from  the  nucleus  to  the  cytoplasm, 
where it can bind to the 3′UTR of CAT-1 mRNA and modulate its 
translation/stability by blocking the miRNA-122 function23. How-
ever, the importance of the interaction between RBM38 and HuR to 
their function and target selection remains largely unexplored.
Although the statistical targeting of Us in vivo, highlighted by 
the  iCLIP  data,  predicts  that  RBM38  targets  U-rich  sequences, 
comparison of the functionally equivalent sites on p21 and c-Myb 
would indicate that the specificity is probably U/G and not U. This 
partial discrepancy can be explained because of the single-stranded 
tendency of U-rich sequences, which are, therefore, more available   
in vivo for proteins targeting single-stranded RNA (ssRNA). Indeed, 
our in vitro binding assays confirm the in vivo target selectivity of 
RBM38 RRM domain for p21 and c-Myb. In this context, the iCLIP 
data confirm the general function and targeting of the protein, but 
they should not be considered as strictly predictive of the sequences 
targeted in vivo. Both the absolute affinity and the affinity differ-
ence between cognate and non-cognate systems indicate that the 
RBM38–RNA  interactions  take  place  within  a  multi-component 
system. We have recently shown that a 20-fold difference in affin-
ity separates a functional and a non-functional interaction in a sys-
tem regulating the peak in c-Myc transcription during cell cycle. 
There, the modest affinity difference allows a precise regulation of 
the length and intensity of the peak of c-Myc concentration. Regula-
tion by RBM38 must also be precise, and the modest affinity differ-
ence between cognate and non-cognate RNAs is probably necessary 
to guarantee a precise and reversible switch of p21 post-transcrip-
tional regulation. Such regulatory mechanisms are typically found 
in multi-component systems. This is consistent with the intermedi-
ate affinity of RBM38 for the specific miRNA target region, which is 
typical of the interaction between an isolated RNA-binding domain 
and ssRNA in multi-component complexes. In vivo, the RBM38 
RRM–RNA binding affinity is likely to be boosted by simultaneous 
interaction of other RNA-binding proteins with the RNA target, 
RBM38 oligomerization or the general structural context38.
Functional impairment of the p53 pathway is instrumental for 
tumour progression. Whereas the p53 pathway is inactivated in most, 
if not all, cancers, the p53 gene is generally mutated in about 50% 
of tumours. However, certain tumours, such as breast and prostate, 
show much lower frequency of mutations in p53. In those tumours, 
other alterations in the p53 pathway occur that weaken p53 tumour-
suppressive activity. Here we propose that RBM38 is important for 
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full p53 function, and that its level of expression correlated with wt 
p53 status. The fact that a significant proportion of wt p53 tumours 
possess DNA methylation of RBM38 promoter region suggests an 
active mechanism to silence RBM38 in those tumours.
Methods
Constructs. Coding sequences were PCR amplified using cDNA pools derived 
from various cell lines and subsequently cloned to pcDNA5/FRT/V5-His TOPO 
(Invitrogene). All UTR sequences were obtained from human genomic DNA PCRs 
and cloned downstream of the Renilla luciferase (Xho1/Not1) in psiCHECK2 
vector. RBM38 knockdown constructs were cloned in pRETROSUPER. p53 knock-
down construct has been previously described39. For the iCLIP, RBM38 ORF was 
cloned (BamH1-Asc1) in pcDNA3pQE vector, downstream of two streptavidin and 
one Histidine tags. To generate a RBM38-HA-inducible cell line, we carboxy-termi-
nally fused the HA epitope (YPYDVPDYA) to RBM38 ORF and cloned (Sal1) the 
coding sequence in the previously described tetracycline-dependent lentiviral vec-
tor40. All primers used to PCR amplify wild-type/mutant RBPs and UTRs as well as 
shRNA and siRNA sequences are listed in Supplementary Table S1.
Cell culture and transfection. HCT116 cells were grown in RPMI and HeLa, 
U2OS, MCF-7, ZR-75.1, MDA-MB-231 and MDA-MB-436 were cultured in 
DMEM containing 10% FBS, penicillin and streptomycin at 37 °C and 5% CO2. The 
screening was setup in a 384-well plate format and performed by reverse-transfect-
ing U2OS cells with 5 ng of psiCHECK2-c-Myb, 10 ng of miRNA and 60 ng of each 
RBP using fugene (Roche). Hits validation, luciferase assays and overexpression/ 
knockdown (pRETROSUPER) experiments were conducted using fugene.  
RNAi experiments were carried out using Dharmafect transfection reagent-1 and 
between 5 to 100 nM of siRNA: Scramble (AUUCGUGAGGCAGAAGCGA), 
RBM38-1 (UGAGAGGGCUUGCAAAGAC), RBM38-2 (GACACCACGUUCA 
CCAAGA) and RBM38-3 (ACGCCUCGCUCAGGAAGUA), RBM38-4 (CGUG 
AACCUGGCAUAUCUG), RBM38-5 (CACCUUGAUCCAGCGGACUUA), 
with or without anti-hsa-miR-17 (AM10198, Ambion) and anti-hsa-miR106b 
(AM10067, Ambion) or hsa-miR-17 duplex (CAAAGUGCUUACAGUGCAG 
GUAG). To induce a p53 stress-response, cells were treated with 0.4 µg ml − 1 of 
doxorubicin (D1515, Sigma), 4–8 µM of Nutlin-3 (N6287, Sigma) or 15 Gy of  
ionizing radiation for 24 h. Inducible GFP and RBM38-HA cell lines were gener-
ated using a tetracycline-dependent lentiviral vector, as previously described40.  
For epigenetic drug treatments, cells were treated with 2 µM 5-aza-2′-deoxy-
cytidine (A3656, Sigma) for 72 h.
Protein analysis. Whole-cell lysates were prepared using Urea lysis buffer  
(6 M Urea, 2% SDS and 50 mM Tris–HCl pH 6.8) and sonication. Protein extract 
concentrations were assessed using the DC protein assay (Bio-Rad). Before electro-
phoresis, protein samples were mixed with laemmli buffer 4×, boiled, SDS/PAGE-
resolved and transferred on PVDF membranes. Protein detection was performed 
using primary antibodies recognizing p53 (DO1, Santa Cruz, 1:1,000), p21 (Sc-397, 
Santa Cruz, 1:1,000), CDK4 (Sc-260, Santa Cruz, 1:1,000), RBM38 (18-003-43641, 
GenWay, 1:2,000), Ago2 (C34C6-Cell Signaling and ab32381-Abcam, 1:1,000 and 
1:300 for IP), V5 (R960-25, Invitrogen, 1:5,000), HA (sc-805/Y-11, Santa Cruz, 
1:1,000, 1:500 for IF and 1:200 for IP), GFP (A6455, Invitrogen, 1:1,000) and  
tubulin (Sc-8035, Santa Cruz, 1:1,000). Membranes were further incubated with 
the appropriate secondary antibodies (Dako) and proteins were visualized using 
ECL reagents (GE Healthcare). For in vitro binding assays, RBM38wt or mutant 
protein (amino acids 23–110, NP_055096) was expressed as a TEV protease- 
cleavable amino-terminal HisTag in E.coli strain BL21 (DE3) using a pETM-11 
vector (EMBL-Heidelberg, Protein Expression Facility). 15N and 15N13C-labelled 
protein was expressed and purified as reported41. Briefly, the tagged protein was  
purified from the soluble fraction of the cell lysate by nickel-affinity chromato-
graphy (Qiagen) and the His-tag removed by overnight TEV protease digestion at 
4 °C, followed by a second nickel affinity step. The RBM38 was further purified by 
gel filtration (Superdex 75 16/60 column, Pharmacia) and finally dialysed overnight 
against the final buffer, 10 mM Tris–HCl pH 7.4, 100 mM NaCl. Protein purity 
as assessed by SDS–PAGE and Coomassie staining was  > 95%. The protein was 
concentrated to 0.6–0.7 mM and stored in 10 mM Tris–HCl pH 7.4, 100 mM NaCl, 
2 mM TCEP, 0.05% (w/v) NaN3 at  − 20 °C.
RNA analysis. Total RNA was isolated using TRIzol reagent (Invitrogen). After 
reverse transcription using oligo dT and SuperScriptII (SSII) reverse transcriptase 
(Invitrogen), real-time quantitative PCR analysis was performed using gene- 
specific primers: RBM38 Fwd (5′-AAGACCCGAACCCCATCATC-3′) Rev  
(5′-CACGATGGCTGGTGGGTAGA-3′), p21 Fwd (5′-TACCCTTGTGCCTCGC 
TCAG-3′) Rev (5′-GAGAAGATCAGCCGGCGTTT-3′), GAPDH Fwd (5′-TGC 
ACCACCAACTGCTTAGC-3′) Rev (5′-GGCATGGACTGTGGTCATGAG-3′) 
and SYBR Green PCR master mix (Applied Bioystems). Mature hsa-miR-17,  
hsa-miR-22, hsa-miR-34a, hsa-miR-107, hsa-miR-150, hsa-miR-200c, hsa- 
miR-222 and hsa-miR-429 were quantified using Taqman microRNA detection assay 
(Applied Biosystems). The 18S ribosomal RNA or GAPDH were used as an internal 
control for real-time PCRs. RNase protection assays for miR-150 were performed 
using the Hybspeed RPA and mirVana kits (Ambion) according to the manufac-
turer’s instructions and the primer 5′-GGCGGCTCCTCTCCCCATGGCCCTG 
TCTCCCAACCCTTGTACCAGTGttttcctgtctc-3′. Cyclophilin probe contained 
nucleotides 46–149 of Accession # BC013915. All reactions were carried out using 
2 µg of RNA extracted from the nuclear and cytoplasmic fractions obtained using 
the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce).
Flow cytometry. Cells were arrested in mitosis using 250 ng ml − 1 nocodazole for 
12 h. Cells were then trypsinized, washed and resuspended in PBS containing 0.6% 
NP-40, 50 mg ml − 1 RNaseA and 50 mg ml − 1 propidium iodide for 10 min. Cell 
cycle profiles were visualized using FACScan and the Cell Quest software (Becton 
Dickinson).
NMR spectroscopy. All NMR samples (15N- and 15N13C-labelled RBM38) were 
prepared in 90% H2O/10% H2O solutions of 10 mM Tris–HCl pH 7.4, 100 mM 
NaCl, 2 mM TCEP at 0.05–0.7 mM protein concentration. The NMR spectra 
were recorded at 37 or 27 °C on Varian Inova and Bruker Avance spectrometers 
equipped with cryoprobes and operating at 600, 700 and 800 MHz 1H frequen-
cies. The spectra were processed with the NMRPipe package42 and analysed using 
Sparky. Backbone assignment of RBM38 at 37 °C was obtained from the analysis of 
HNCACB, CBCA(CO)NH and HNCO experiments as described in refs 43 and 44.
In vitro binding analysis. Chemically synthesized (Thermo Scientific) RNA  
22-mers recapitulating c-Myb, p21 and SIRT1 miRNA-binding sites were titrated 
into 25 or 50 µM sample of 15N- labelled RBM38 in 10 mM Tris–HCl pH 7.4, 
100 mM NaCl, 2 mM TCEP and the recommended amount of RNasin (Promega).  
Protein–RNA binding was monitored by recording 15N 1H correlation spectra at 
0:1, 0.5:1, 1:1, 2:1, 4:1 and 8:1 RNA:protein ratios and measuring chemical shift 
changes of six resonances in fast exchange regime on an NMR timescale. The 
averaged chemical shift change of the resonances was calculated using the equation 
∆δavg = ((∆δN/10)2 + ∆δH
2)1/2 and was plotted against the RNA:protein ratio to obtain 
the binding isotherms. Binding constants were obtained using the program xcrvfit 
(Sykes Laboratory) assuming a single site of binding.
iCLIP. The procedure used for the iCLIP has been previously described33. A total of 
13,386 binding sites were mapped to validated protein-coding transcripts. Search 
for binding site signature was done using the AMADEUS de-novo motif discovery 
package45. Over-represented motifs were searched in the binding-site regions 
(defined as the 16-nt-long regions centred at the location mapped by iCLIP as the 
binding nucleotide) compared with their flanking sequences of the same length 
and on both sides of the binding region.
RNA immunoprecipitation. GFP and RBM38-HA clones were induced with Dox-
ycycline (1 µg ml − 1 for 24 h) and treated with Nutlin-3 (8 µM for 12 h). Before lysis, 
cells were crosslinked 15 min with 1% formaldehyde, inactivated with 330 mM 
glycine, washed with PBS and resuspended in lysis buffer (50 mM Hepes pH 7.5, 
150 mM NaCl, 1% Triton X-100, 0.1% Sodium deoxycholate) supplemented with 
protease inhibitor mixture (Roche), RNaseOUT (Invitrogen) and 1 mM dithioth-
reitol. The extracts were then sonicated, insoluble materials discarded and protein 
concentrations assessed. For each condition, Ago2 was immunoprecipitated from 
2 mg of cell extract using 2 µg of antibody and Gammabind G sepharose (GE 
Healthcare) beads preblocked with 5% BSA. Extracts were incubated 5 h in a tum-
bler placed at 4 °C. After extensive washing, reverse crosslinking was performed 5 h 
at 70 °C and RNA was extracted (Trizol, Invitrogen) to be subjected to RT–qPCR.
Fluorescence microscopy. Microscope cover slips were placed in polylysine- 
coated six-well culture dishes. The cells were then plated at a density of 5×105 cells 
per well and allowed to adhere for 24 h before induction (Doxycycline, 1 µg ml − 1). 
Cells were fixed with 3% formaldehyde and subsequently permeabilized with 
PBS-Triton X-100 (0.3%) solution. After blocking 1 h with 2% PBS-Milk, the HA 
epitope was detected using the aforementioned primary antibodies and the Alexa 
Fluor 488 Dye-conjugated secondary antibody. Images were captured using an  
AxioCam MRc CCD camera (Carl Zeiss Microimaging).
Microarray analysis. Expression profiles were recorded in independent duplicates 
using Illumina WG6v3 arrays containing more than 49 K probes. Expression 
levels were calculated using Illumina’s BeadStudio package. Only probes flagged as 
‘Present’ (detection P-value  < 0.05) in at least two out of the eight arrays were used 
for subsequent analysis (24,630 probes). Arrays were normalized using quantile 
normalization. Expression dataset was then analysed using the EXPANDER pack-
age46. Probes that responded to doxorubicin treatment by at least a factor of 2.0 
were subjected to k-means cluster analysis (2,990 probes). GO enrichment analysis 
was carried out using TANGO. The microarray data has been deposited in the 
Gene Expression Omnibus (GEO) database under accession code GSE32301.
DNA methylation analysis. CpG islands were identified in silico using Methyl 
Primer Express v1.0 software. DNA methylation status was established by bisulfite 
genomic sequencing of multiple clones or methylation-specific PCRs in DNA sam-
ples previously treated with sodium bisulfite (EZ DNA methylation Gold kit, Zymo 
Research). The primers used are listed in Supplementary Table S1. ARTICLE     
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